1. Both male and female patients aged between 18-55 years who signed the informed consent. <br/ >2. Patients screened for Covid-19 by RT-PCR method â?¤72 hours from the date <br/ >of RT-PCR confirmation and/or 7 days from the start of symptoms. <br/ >3. Respiratory Rate > 24 breaths/min and SpO2 â?¤93% on room air <br/ >4. Patients screened for intradermal sensitivity testing prior to initiation of infusion.

1. Both male and female patients aged between 18-55 years who signed the informed consent. <br/ >2. Patients screened for Covid-19 by RT-PCR method â?¤72 hours from the date <br/ >of RT-PCR confirmation and/or 7 days from the start of symptoms. <br/ >3. Respiratory Rate > 24 breaths/min and SpO2 â?¤93% on room air <br/ >4. Patients screened for intradermal sensitivity testing prior to initiation of infusion.

1. Both male and female patients aged between 18-55 years who signed the informed consent. <br/ >2. Patients screened for Covid-19 by RT-PCR method â?¤72 hours from the date <br/ >of RT-PCR confirmation and/or 7 days from the start of symptoms. <br/ >3. Respiratory Rate > 24 breaths/min and SpO2 â?¤93% on room air <br/ >4. Patients screened for intradermal sensitivity testing prior to initiation of infusion.

1. Both male and female patients aged between 18-55 years who signed the informed consent. <br/ >2. Patients screened for Covid-19 by RT-PCR method â?¤72 hours from the date <br/ >of RT-PCR confirmation and/or 7 days from the start of symptoms. <br/ >3. Respiratory Rate > 24 breaths/min and SpO2 â?¤93% on room air <br/ >4. Patients screened for intradermal sensitivity testing prior to initiation of infusion.